Top in hem/onc: Right to Try vs. Expanded Access, priority review of thyroid cancer drug
Click Here to Manage Email Alerts
Recent data revealed the Right to Try track did not more successfully help oncologists obtain investigational drugs than Expanded Access, which has an extra step of receiving FDA authorization for each patient.
A report on the data was the top story in hematology/oncology last week.
Another top story was about the FDA granting priority review to cabozantinib (Cabometyx, Exelixis), a multitargeted tyrosine kinase inhibitor, for differentiated thyroid cancer treatment. A planned interim analysis of a randomized phase 3 trial showed that 60 mg of cabozantinib was associated with a statistically significant improvement in progression-free survival compared with placebo, according to the manufacturer.
Read these and more top stories in hematology/oncology below:
Right to Try fails to show ‘edge’ vs. Expanded Access pathway among community oncologists
Use of the Right to Try pathway did not improve community oncologists’ ability to obtain investigational drugs compared with the FDA’s Expanded Access pathway, according to study results in JCO Oncology Practice. Read more.
FDA grants priority review to Cabometyx for differentiated thyroid cancer
The FDA granted priority review to cabozantinib for the treatment of certain patients with differentiated thyroid cancer. Read more.
FDA grants priority review to Tecentriq for early NSCLC
The FDA granted priority review to atezolizumab (Tecentriq, Genentech/Roche) as adjuvant treatment for certain people with non-small cell lung cancer. Read more.
Bristol Myers Squibb withdraws peripheral T-cell lymphoma indication for romidepsin
Bristol Myers Squibb withdrew the indication for romidepsin (Istodax) as a treatment for relapsed or refractory peripheral T-cell lymphoma. Read more.
FDA grants priority review to Keytruda for stage II resected high-risk melanoma
The FDA granted priority review to pembrolizumab (Keytruda, Merck) for adjuvant treatment of certain patients with high-risk melanoma. Read more.